巨细胞动脉炎——新的治疗目标即将出现。

IF 4.6 2区医学 Q1 RHEUMATOLOGY

Seminars in arthritis and rheumatism Pub Date : 2025-02-27 DOI:10.1016/j.semarthrit.2025.152686

Jens Thiel

{"title":"巨细胞动脉炎——新的治疗目标即将出现。","authors":"Jens Thiel","doi":"10.1016/j.semarthrit.2025.152686","DOIUrl":null,"url":null,"abstract":"<div><div>Increasing insights into the pathogenesis of giant cell arteritis (GCA) identified a large number of new treatment targets. Very recently clonal hematopoesis, immune ageing processes associated with inflammation and dysregulated immune checkpoints have been linked to the pathogenesis of GCA. Based on pathopyhsiological insights new treatment options such as Janus kinase inhibitors or IL-17A blocking antibodies are currently tested in GCA.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152686"},"PeriodicalIF":4.6000,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Giant cell arteritis – New treatment targets at the horizon\",\"authors\":\"Jens Thiel\",\"doi\":\"10.1016/j.semarthrit.2025.152686\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Increasing insights into the pathogenesis of giant cell arteritis (GCA) identified a large number of new treatment targets. Very recently clonal hematopoesis, immune ageing processes associated with inflammation and dysregulated immune checkpoints have been linked to the pathogenesis of GCA. Based on pathopyhsiological insights new treatment options such as Janus kinase inhibitors or IL-17A blocking antibodies are currently tested in GCA.</div></div>\",\"PeriodicalId\":21715,\"journal\":{\"name\":\"Seminars in arthritis and rheumatism\",\"volume\":\"72 \",\"pages\":\"Article 152686\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2025-02-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Seminars in arthritis and rheumatism\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0049017225000575\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in arthritis and rheumatism","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0049017225000575","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

巨细胞动脉炎（GCA）发病机制的深入研究发现了大量新的治疗靶点。最近克隆造血、与炎症和免疫检查点失调相关的免疫老化过程与GCA的发病机制有关。基于病理生理学的见解，新的治疗方案如Janus激酶抑制剂或IL-17A阻断抗体目前正在GCA中进行测试。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Giant cell arteritis – New treatment targets at the horizon

Increasing insights into the pathogenesis of giant cell arteritis (GCA) identified a large number of new treatment targets. Very recently clonal hematopoesis, immune ageing processes associated with inflammation and dysregulated immune checkpoints have been linked to the pathogenesis of GCA. Based on pathopyhsiological insights new treatment options such as Janus kinase inhibitors or IL-17A blocking antibodies are currently tested in GCA.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Seminars in arthritis and rheumatism 医学-风湿病学

CiteScore

9.20

自引率

4.00%

发文量

176

审稿时长

46 days

期刊介绍： Seminars in Arthritis and Rheumatism provides access to the highest-quality clinical, therapeutic and translational research about arthritis, rheumatology and musculoskeletal disorders that affect the joints and connective tissue. Each bimonthly issue includes articles giving you the latest diagnostic criteria, consensus statements, systematic reviews and meta-analyses as well as clinical and translational research studies. Read this journal for the latest groundbreaking research and to gain insights from scientists and clinicians on the management and treatment of musculoskeletal and autoimmune rheumatologic diseases. The journal is of interest to rheumatologists, orthopedic surgeons, internal medicine physicians, immunologists and specialists in bone and mineral metabolism.